Reuters - Video

エディション: US | UK | IN | CN | JP

video

Breakingviews TV: Biogen fail

2019年 3月 22日 Friday - 03:26

The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.

▲ ストーリーを隠す

ストーリーを表示する

The abandonment of Biogen’s Alzheimer’s drug, which cost it $18 billion in market value, follows the failure of similar efforts by others. It’s a potentially huge market, but a tough one to crack. Rob Cyran explains why investors may have been too optimistic.

リンクをコピーするには:URL上で右クリック後「コピー」を選択。モバイル端末では、URLを長押ししてください。

Breakingviews TV: Biogen fail

2019年 3月 22日 Friday - 03:26